Clinical Trial Update: Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase Ib trial evaluating erlotinib given before surgery in patients with recurrent head and neck cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Salivary Gland Carcinoma
• Skin Squamous Cell Carcinoma

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Head and Neck Carcinoma, Recurrent Salivary Gland Carcinoma | Phase 1 | Status: COMPLETED